Target Name: RBM10
NCBI ID: G8241
Review Report on RBM10 Target / Biomarker Content of Review Report on RBM10 Target / Biomarker
RBM10
Other Name(s): RBM10 variant 3 | RNA binding motif protein 10, transcript variant 5 | RNA-binding protein 10 (isoform 5) | RBM10_HUMAN | g patch domain-containing protein 9 | epididymis secretory sperm binding protein | RBM10 variant 1 | MGC997 | RNA binding motif protein 10, transcript variant 1 | Epididymis secretory sperm binding protein | RNA binding motif protein 10, transcript variant 3 | RBM10 variant 5 | RNA-binding protein 10 | RNA-binding protein S1-1 | DXS8237E | MGC1132 | RNA-binding protein 10 (isoform 1) | KIAA0122 | G patch domain-containing protein 9 | RNA-binding motif protein 10 | S1-1 | ZRANB5 | RNA binding motif protein 10 | GPATC9 | TARPS | MINAS-60 | RNA-binding protein 10 (isoform 3) | GPATCH9

RBM10: A Promising RNA Molecule for Drug Targets and Biomarkers

The research on RNA-based biomarkers has been rapidly evolving in recent years due to the increasing interest in the development of novel diagnostic tools and therapeutic approaches. One of the promising areas of study is the use of RNA variants, such as RBM10, as drug targets or biomarkers. In this article, we will discuss the RBM10 molecule, its functions, potential drug targets, and clinical applications.

Potential Drug Target and Biomarker

RBM10 is a RNA molecule that has been identified as a potential drug target and biomarker. It is derived from the M1 RNA gene, which is a non-coding RNA molecule that is expressed in various tissues and cells throughout the body. RBM10 has been shown to play a critical role in cell signaling and has been linked to the development and progression of various diseases, including cancer.

One of the key features of RBM10 is its ability to interact with various signaling pathways, including TGF-β, NF-kappa-B, and NF-epoxide signaling pathways. It has been shown to play a negative role in the regulation of these pathways and has been shown to promote the growth and survival of cancer cells.

In addition to its role in cell signaling, RBM10 has also been shown to be involved in the regulation of gene expression and has been linked to the development of various diseases, including cancer. For example, studies have shown that RBM10 can interact with the tumor suppressor gene PDGF-BB and promote its expression, leading to the development of cancer.

Potential Applications

The potential applications of RBM10 as a drug target or biomarker are vast and range from cancer research to the development of diagnostic tools. One of the most promising areas of study is the use of RBM10 as a drug target for cancer therapy.

Studies have shown that RBM10 can be overexpressed in various cancer types, including breast, lung, and ovarian cancer. This overexpression has been shown to promote the growth and survival of cancer cells and can lead to the development of Resistance to cancer treatments. Therefore, Targeting RBM10 with small molecules or antibodies has the potential to be a valuable cancer therapeutic approach.

In addition to its potential as a cancer therapeutic, RBM10 has also been shown to be involved in the development of diagnostic tools. Its expression has been shown to be associated with various diseases, including cancer, and its levels have been shown to be decreased in the blood of patients with various diseases. Therefore, measuring the expression of RBM10 may be a useful diagnostic tool for the diagnosis of certain diseases.

Conclusion

In conclusion, RBM10 is a promising molecule that has the potential to be a drug target or biomarker. Its ability to interact with various signaling pathways and its involvement in the regulation of gene expression make it an attractive target for cancer therapy. Additionally, its potential as a diagnostic tool makes it an important area of 鈥嬧?媟esearch for the development of new diagnostic tools and techniques. Further studies are needed to fully understand the functions of RBM10 and its potential as a drug target or biomarker.

Protein Name: RNA Binding Motif Protein 10

Functions: Acts as a late-stage inhibitor of pre-60S ribosome assembly by preventing pre-60S ribosome export from nucleus

The "RBM10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBM10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1 | RCHY1 | RCL1 | RCN1 | RCN1P2 | RCN2 | RCN3 | RCOR1 | RCOR2 | RCOR3 | RCSD1